有效白蛋白概念、检测及其临床应用前景*

doi:10.3969/j.issn.1672-5069.2024.02.002

实用肝脏病杂志 ›› 2024, Vol. 27 ›› Issue (2): 165-168.doi: 10.3969/j.issn.1672-5069.2024.02.002

有效白蛋白概念、检测及其临床应用前景^*

张舒茜, 谢雯

100015 北京市首都医科大学附属北京地坛医院肝病中心

收稿日期:2023-09-28 出版日期:2024-02-10 发布日期:2024-03-08
通讯作者: 谢雯,E-mail:xiewen6218@163.com
作者简介:张舒茜,内科学(传染病学方向)硕士研究生
基金资助:
^*首都卫生发展基金资助项目(编号:首发2022-2-2174);北京市医管局消化内科学科协同发展中心重点科研项目(编号:XXZ04);北京市科委重大科研项目(编号:D171100003117005)

Definition, detection and clinical application of effective albumin

Zhang Shuqian, Xie Wen

Center of Liver Diseases, Ditan Hospital, Capital Medical University, Beijing 100015 China

Received:2023-09-28 Online:2024-02-10 Published:2024-03-08

摘要/Abstract

关键词: 肝硬化, 有效白蛋白, 临床应用

Key words: Liver cirrhosis, Effective albumin, Clinical application

张舒茜, 谢雯. 有效白蛋白概念、检测及其临床应用前景^*[J]. 实用肝脏病杂志, 2024, 27(2): 165-168.

Zhang Shuqian, Xie Wen. Definition, detection and clinical application of effective albumin[J]. Journal of Practical Hepatology, 2024, 27(2): 165-168.

[1] Jagdish RK, Maras JS, Sarin SK. Albumin in advanced liver diseases: The good and bad of a drug. Hepatology, 2021, 74(5): 2848-2862.
[2] Jalan R, Bernardi M. Effective albumin concentration and cirrhosis mortality: from concept to reality. J Hepatol, 2013, 59(5): 918-920.
[3] European Association for the Study of the Liver.EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol, 2018, 69(2): 406-460.
[4] Gines P, Krag A, Abraldes JG, et al. Liver cirrhosis. Lancet, 2021, 398(10308): 1359-1376.
[5] Thevenot T, Bureau C, Oberti F, et al. Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial. J Hepatol, 2015, 62(4): 822-830.
[6] Aithal GP, Palaniyappan N, China L, et al. Guidelines on the management of ascites in cirrhosis. Gut, 2021, 70(1): 9-29.
[7] Arora V, Vijayaraghavan R, Maiwall R, et al. Paracentesis-induced circulatory dysfunction with modest-volume paracentesis is partly ameliorated by albumin infusion in acute-on-chronic liver failure. Hepatology, 2020, 72(3): 1043-1055.
[8] Caraceni P, Riggio O, Angeli P, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet, 2018, 391(10138): 2417-2429.
[9] De Simone G, Di Masi A, Ascenzi P. Serum albumin: A multifaced enzyme. Int J Mol Sci, 2021, 22(18): 10086.
[10] Belinskaia DA, Voronina PA, Goncharov NV. Integrative role of albumin: Evolutionary, biochemical and pathophysiological aspects. J Evol Biochem Physiol, 2021, 57(6): 1419-1448.
[11] Domenicali M, Baldassarre M, Giannone FA, et al. Posttranscriptional changes of serum albumin: clinical and prognostic significance in hospitalized patients with cirrhosis. Hepatology, 2014, 60(6): 1851-1860.
[12] Xiao LL, Zhang F, Zhao YL, et al. Using advanced oxidation protein products and ischaemia-modified albumin to monitor oxidative stress levels in patients with drug-induced liver injury. Sci Rep, 2020, 10(1): 18128.
[13] Das S, Maras JS, Hussain MS, et al. Hyperoxidized albumin modulates neutrophils to induce oxidative stress and inflammation in severe alcoholic hepatitis. Hepatology, 2017, 65(2): 631-646.
[14] Rodriguez EL, Tao P, Woolfork AG, et al. Studies of binding by sulfonylureas with glyoxal- and methylglyoxal-modified albumin by immunoextraction using affinity microcolumns. J Chromatogr A, 2021, 1638: 461683.
[15] Handy,Loscalzo J. The role of glutathione peroxidase-1 in health and disease. Free Radic Biol Med, 2022, 188: 146-161.
[16] Shevtsova A, Gordiienko I, Tkachenko V, et al. Ischemia-modified albumin: Origins and clinical implications. Dis Markers, 2021, 2021: 9945424.
[17] Quinlan GJ, Martin GS, Evans TW. Albumin: biochemical properties and therapeutic potential. Hepatology, 2005, 41(6): 1211-1219.
[18] Baldassarre M, Naldi M, Zaccherini G, et al. Determination of effective albumin in patients with decompensated cirrhosis: Clinical and prognostic implications. Hepatology, 2021, 74(4): 2058-2073.
[19] Lee P, Wu X. Modifications of human serum albumin and their binding effect. Curr Pharm Des, 2015, 21(14): 1862-1865.
[20] Taverna M, Mira JP, Marie AL, et al. Specific antioxidant properties of human serum albumin. Ann Intensive Care, 2013, 3: 4.
[21] Baldassarre M, Domenicali M, Naldi M, et al. Albumin homodimers in patients with cirrhosis: Clinical and prognostic relevance of a novel identified structural alteration of the molecule. Sci Rep, 2016, 6(1): 35987.
[22] Paar M, Fengler VH, Reibnegger G, et al. Determination of binding characteristics as a measure for effective albumin using different methods. Biochim Biophys Acta Gen Subj, 2023, 1867(9): 130427.
[23] Oettl K, Spinelboeck W, Dorn L, et al. Oxidative albumin damage in chronic liver failure: relation to albumin binding capacity, liver dysfunction and survival. J Hepatol, 2013, 59(5): 978-983.
[24] Yavuz F, Biyik M, Asil M, et al. Serum ischemic modified albumin (IMA) concentration and IMA/albumin ratio in patients with hepatitis B-related chronic liver diseases. Turk J Med Sci, 2017, 47(3): 947-953.
[25] Volmer J, Arabi SH, Henning C, et al. Tuning human serum albumin (HSA) hydrogels through albumin glycation. Macromol Biosci, 2023, 23(3): e2200487.
[26] Jalan R, Schnurr K, Mookerjee RP, et al. Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. Hepatology, 2009, 50(2): 555-564.
[27] Brown KA, Melby JA, Roberts DS, et al. Top-down proteomics: challenges, innovations, and applications in basic and clinical research. Expert Rev Proteomics, 2020, 17(10): 719-733.
[28] Rahali MA, Lakis R, Sauvage FL, et al. Posttranslational-modifications of human-serum-albumin analysis by a top-down approach validated by a comprehensive bottom-up analysis. J Chromatogr B Analyt Technol Biomed Life Sci, 2023, 1224: 123740.
[29] Tada S, Yasukawa K, Yatomi Y, et al. A simple colorimetric assay to determine the concentration and proportion of human mercaptalbumin. Pract Lab Med, 2022, 31: e00281.
[30] Lakis R, Sauvage FL, Pinault E, et al. Semi-synthetic human albumin isoforms: Production, structure, binding capacities and influence on a routine laboratory test. Int J Biol Macromol, 2023: 126239.
[31] Tabata F, Wada Y, Kawakami S, et al. Serum albumin redox states: More than oxidative stress biomarker. Antioxidants (Basel), 2021, 10(4): 503.
[32] Nagumo K, Tanaka M, Chuang VT, et al. Cys34-cysteinylated human serum albumin is a sensitive plasma marker in oxidative stress-related chronic diseases. PLoS One, 2014, 9(1): e85216.
[33] Liu H, Ju A, Dong X, et al. Young and undamaged recombinant albumin alleviates T2DM by improving hepatic glycolysis through EGFR and protecting islet beta cells in mice. J Transl Med, 2023, 21(1): 89.
[34] Mori F, Natali L, Danesi R, et al. Post-translational modifications and antioxidant properties of different therapeutic human serum albumins. Int J Biol Macromol, 2021, 183: 927-935.
[35] Tang J, Ju A, Li B, et al. Young and undamaged rMSA improves the healthspan and lifespan of mice. Biomolecules, 2021, 11(8): 1191.

有效白蛋白概念、检测及其临床应用前景^*

Definition, detection and clinical application of effective albumin

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	徐京杭, 于岩岩, 徐小元. 肝硬化临床研究进展[J]. 实用肝脏病杂志, 2024, 27(2): 161-164.
[2]	卜玲玲, 殷燕, 潘丹烨, 陈晨. 自身免疫性肝炎与原发性胆汁性肝硬化合并干燥综合征患者临床特征比较^*[J]. 实用肝脏病杂志, 2024, 27(2): 206-209.
[3]	李尧, 梁健, 张春, 董静, 陈照林, 周旭, 娄方明, 杨小康, 刘波, 宋海燕. 恩替卡韦联合聚乙二醇干扰素-α2b治疗代偿期乙型肝炎肝硬化患者疗效研究[J]. 实用肝脏病杂志, 2024, 27(2): 226-229.
[4]	王红霞, 胥晓倩, 于明帅. 内镜下硬化剂治疗乙型肝炎肝硬化并发食管胃底静脉曲张破裂出血患者应用不同剂量羟考酮联合丙泊酚靶控输注麻醉效果研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 230-233.
[5]	万贵香, 李忠廉, 赵亚博, 梁微微, 杜辉, 宁振海, 周媛, 万亮. 恩替卡韦联合扶正解毒散结方治疗乙型肝炎肝硬化患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 234-237.
[6]	肖潇, 盛云建. 内镜下曲张静脉套扎术联合经颈静脉肝内门体静脉分流术治疗肝硬化食管胃底静脉曲张破裂出血患者效果研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 238-241.
[7]	朱春芬, 任春霖, 郭霞. 血清NT-ProBNP和TnI联合心电图检查早期诊断肝硬化性心肌病价值研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 242-245.
[8]	冯彦菲, 苏明华, 殷倩冰, 黎清梅, 苏土梅, 梁蘅恺, 韦璐, 黄建芳, 江建宁. 一组非肝硬化性门静脉高压症病因分析和诊断路径探讨^*[J]. 实用肝脏病杂志, 2024, 27(2): 246-250.
[9]	王兵, 肖元初, 孙振纲, 王帅. 倾向性评分匹配腹腔镜肝叶切除术与开腹术治疗合并肝硬化的肝胆管结石患者临床疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 303-306.
[10]	靳珂珂, 丁惠国. 肝硬化门静脉血栓形成风险监测及抗凝管理^*[J]. 实用肝脏病杂志, 2024, 27(1): 3-6.
[11]	鲁文婷, 张峰. 非肝硬化门静脉系统血栓形成临床管理[J]. 实用肝脏病杂志, 2024, 27(1): 7-10.
[12]	张明. 肝硬化门静脉血栓形成诊治新进展[J]. 实用肝脏病杂志, 2024, 27(1): 11-15.
[13]	穆玉娟, 吴斐斐, 陈莹. 磁共振增强T1 mapping和IVIM-DWI技术评估乙型肝炎肝硬化患者肝脏储备功能价值研究^*[J]. 实用肝脏病杂志, 2024, 27(1): 68-71.
[14]	宋一凡, 郑帅, 许芸, 唐铁骑. 超声半定量评分结合瞬时弹性成像技术评估乙型肝炎肝硬化并发食管静脉曲张价值研究^*[J]. 实用肝脏病杂志, 2024, 27(1): 72-75.
[15]	李新力, 秦长江, 尹方方. 特利加压素治疗肝硬化并发食管胃静脉曲张破裂出血患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(1): 76-79.